Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Stopped early · Phase 1/Phase 2
Conditions studied: Non-small Cell Lung Cancer Adenocarcinoma
In brief
This study will be conducted in adult participants diagnosed with NSCLC who have been previously treated for a minimum of 12 weeks with any PD-1 or PD-L1 checkpoint inhibitor. This is a phase 1b/2, multi-center, open label study designed to assess safety and tolerability of grapiprant in combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with pembrolizumab, and to evaluate disease response with grapiprant based on investigator assessments. Pharmacokinetics, pharmacodynamics and response biomarkers will also be assessed.
Key facts
- Study ID
- NCT03696212
- Run by
- Arrys Therapeutics
- People needed
- 18
- Starts
- 2019-01-08
- Expected to finish
- 2021-02-15
- Last updated by the study team
- 2021-02-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University Medical Center — Stanford, California, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- START Midwest — Grand Rapids, Michigan, United States
- University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.